Disclosures: Peyton Classon: Nothing to Disclose, Sophia Jaramillo: Nothing to Disclose, Danielle Carlson: Nothing to Disclose, Irene Yan: Nothing to Disclose, Sumera Ilyas: Astrazeneca: Consultant, Rory Smoot: Nothing to Disclose, Gregory Gores: Nothing to Disclose, Tushar Patel: Nothing to Disclose, Davide Povero: Nothing to Disclose 1831 T CELL RECEPTOR AND IMMUNE GENE EXPRESSION PHARMACODYNAMICS FOR DURVALUMAB MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB OR BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) Robin Kate Kelley 1 Young Lee 2 James Conway 2 John Kurland 2 Alejandra Negro 2 Patricia McCoon 3 , 1 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA, 2 Oncology R&D, AstraZeneca, Gaithersburg, MD, USA, 3 Oncology R&D, AstraZeneca, Waltham, MA, USA Background: Study 22 (NCT02519348), a Phase 2 trial of immune checkpoint inhibitor (ICI) monotherapy and combination regimens in uHCC, showed higher rates of objective response (ORR) with STRIDE (Single Tremelimumab [T] Regular Interval Durvalumab [D]) or D+bevacizumab (B) than with D
Similar content being viewed by others Introduction For over several thousand years, garlic has been consumed by humans not only as a kind of flavoring food but also as a medicinal food or a topical agent
Of the 6 myo-inositol mQTLs identified, all had been previously associated with higher myo-inositol levels based on review of the GWAS catalog
Schedule Your Complimentary Consultation
Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JO: Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke
